Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat populationCompany ...

The company said that the designation is supported by clinical data which demonstrates a 33% objective response rate for ...